Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Heparin Na
Indication
Prophylaxis of re-occlusion of the coronary arteries following thrombolytic therapy in myocardial infarction, Peripheral arterial embolism, Unstable angina, Venous thromboembolism, Prophylaxis of postoperative venous thromboembolism, Venous thromboembolism.
Instruction
Administer via IV and Subcutaneous.
Drug interaction
Enhanced anticoagulant effect w/ other drugs affecting platelet function or the coagulation system (e.g. platelet aggregation inhibitors, thrombolytic agents, salicylates, NSAIDs, vit K antagonists, dextrans, activated protein C). Decreased anticoagulant effect w/ gyceryl trinitrate infusion. Increased risk of hyperkalaemia w/ ACE inhibitors or angiotensin II antagonists.
Malaysia
